Continue Reading

In this case report, the combination of apatinib and TMZ exerted good efficacy and safety in the treatment of a melanoma patient with KIT mutation in exon 11, who had progressed after the second-line chemotherapy. As NGS analysis did not find any other gene mutations, KIT might be the patient’s driver gene, suggesting that routine screening of acral melanoma for KIT mutation may open up new treatment choice for those patients. Considering apatinib has multiple mechanisms in anti-tumor effect, it is possible that apatinib plus TMZ might be a feasible option in metastatic melanoma with KITmutation in exon 11. Large prospective trials are needed to confirm the efficacy and safety of apatinib and TMZ combination therapy for MM treatment in the future.


We thank the patient for his participation and his agreement and written informed consent for publication of his information and accompanying images in this case report. We also thank Burning Rock Biotech for doing NGS analysis. This research was supported by the National Natural Science Foundation of China (grant number 81372210) and the Natural Science Foundation of Zhejiang Province (grant number LY15H160003).


The authors report no conflicts of interest in this work.

Cong Luo,1 Jiayu Shen,2 Jieer Ying,1 Xianhua Fang,3 Xiaohong Wang,1 Zhixuan Fu,4 Peng Liu5
1Department of Abdominal Oncology, Zhejiang Cancer Hospital, 2The Second Clinical Medical College, Zhejiang Chinese Medical University, 3Department of Pathology, 4Department of Colorectal Surgery, 5Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China 


1. Zebary A, Omholt K, Vassilaki I, et al. KIT, NRAS, BRAF, and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci. 2013;72(3):284–289.

2. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191–2199.

3. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94(12):894–903.

4. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158–166.

5. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest. 2003;21(6):821–829.

6. Luo C, Shen J. Research progress in advanced melanoma. Cancer Lett. 2017;397:120–126.

7. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19(2):577–583.

8. Cui C, Mao L, Chi Z, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther. 2013;21(7):1456–1463.

9. Piperno-Neumann S, Diallo A, Etienne-Grimaldi MC, et al. Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma. Oncologist. 2016;21(3):281–282.

10. Kottschade LA, Suman VJ, Perez DG, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775. Cancer. 2013;119(3):586–592.

11. von Moos R, Seifert B, Simcock M, et al. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol. 2012;23(2):531–536.

12. Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro, and in vivo. Cancer Sci. 2011;102(7):1374–1380.

13. Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70(20):7981–7991.

14. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001;61(9):3819–3825.

15. Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol. 2009;24(5):643–650.

16. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification. J Clin Oncol. 2011;29(21):2904–2909.

17. Ji G, Hong L, Yang P. Successful treatment of angiosarcoma of the scalp with apatinib: a case report. Onco Targets Ther. 2016;9:4989–4992.

18. Dong M, Bi J, Liu X, Wang B, Wang J. Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: a case report. Medicine. 2016;95(31):e4368.

Source: OncoTargets and Therapy.
Originally published September 14, 2017.